Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the liver cancer diagnostics market grown over the years?

In recent times, there has been a robust growth in the liver cancer diagnostics market size. It is projected to increase from $9.69 billion in 2024 to $10.4 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The historic growth can be credited to biopsy techniques and histopathology, the advancement of biomarker detection, the evolution of screening programs, advancements in genetic testing, and improvements in liver imaging modalities.

What Is the forecasted market size and growth rate for the liver cancer diagnostics market?

In the coming years, the liver cancer diagnostics market is projected to experience robust growth. It is forecasted to reach $13.86 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be associated with regulatory alterations and standardization, the increased significance of imaging modalities, the advent of next-generation sequencing, the extension of screening programs and awareness, and the growing demand for biomarker-based tests. Among the significant trends during the forecast period are increasing incidence and prevalence, improved imaging technologies, emphasis on non-invasive diagnostics, precision medicine, personalized diagnostics, and the incorporation of artificial intelligence (AI).

Get your liver cancer diagnostics market report here!

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

What are the major factors driving growth in the liver cancer diagnostics market?

The continuous increase of liver cancer cases is anticipated to stimulate the expansion of the liver cancer diagnostics market. Liver cancer, a deadly disease, happens when the liver cells proliferate uncontrollably. Diagnostic examinations for liver cancer are conducted to ascertain if cancer cells have proliferated within or around the liver following the initial diagnosis of liver carcinoma, hence the continuous increase of liver cancer cases is enhancing the liver cancer diagnostics market. In January 2023, the American Cancer Society, a US voluntary health organization, reported in its Cancer Facts & Figures 2023 report, that new cases of liver and intrahepatic bile duct cancer in women rose to 13,230 in 2023, from 12,640 in 2020, recorded in the United States. In addition, an estimated 41,210 new liver cancer cases were anticipated for 2023 in the US, with an expected death toll of 29,380 individuals. Therefore, the escalating cases of liver cancer are the main factor pushing the growth of the liver cancer diagnostic market.

What key areas define the segmentation of the global liver cancer diagnostics Market?

The liver cancer diagnostics market covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types

2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings

3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Subsegments:

1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma

4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What are the top market players propelling the growth of the liver cancer diagnostics industry?

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

What are the key trends shaping the future of the liver cancer diagnostics market?

Key players in the liver cancer diagnostics market are striving to improve diagnostic accuracy and early detection by creating sophisticated assays and algorithms based on biomarkers. Biomarker-focused assays and algorithms are diagnostics tools that use special biological markers to recognize diseases, thus increasing the precision and efficiency of diagnosis. For example, in November 2023, Roche Diagnostics, a leading biotech firm in the US, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The former recognizes elevated PIVKA-II biomarker levels, which are linked with hepatocellular carcinoma (HCC), thus enhancing the early detection of liver cancer in patients at high risk. The latter algorithm mingles multiple diagnostic markers like PIVKA-II and AFP to boost diagnostic accuracy and simplify decision-making during the detection of liver cancer.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10481

What regions are dominating the liver cancer diagnostics market growth?

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Transplant Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

Cervical Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Precision Medicine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: